Investigational drug · Phase 3
VX-121
Also called: D-IVA, CTP-656, VX-561, VNZ
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cystic Fibrosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
12
Any phase or sponsor naming "VX-121"
First trial start
2022
Jun 21, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VX-121", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cystic Fibrosis
Approved drugs for the same conditions: Cystic fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "VX-121" as an intervention, largest first.
- A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyPivotal-lookingActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05444257 · 822 participants · Start Nov 8, 2022 · Primary completion Oct 30, 2026
Drug: VX-121/TEZ/D-IVA · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 195 sites in all
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05076149 · 597 participants · Start Oct 27, 2021 · Primary completion May 18, 2023
Drug: VX-121/TEZ/D-IVA; ELX/TEZ/IVA and 4 more · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 170 sites in all
- A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)Pivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05033080 · 435 participants · Start Sep 14, 2021 · Primary completion May 12, 2023
Drug: VX-121/TEZ/D-IVA; ELX/TEZ/IVA and 4 more · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 139 sites in all
- Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of AgePivotal-lookingActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05422222 · 210 participants (planned) · Start Jun 21, 2022 · Primary completion Jun 30, 2030
Drug: VX-121/TEZ/D-IVA · For: Cystic Fibrosis
Sites: Orange, California; Palo Alto, California; Aurora, Colorado · 38 sites in all
- Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and OlderPivotal-lookingEnrolling by invitation
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05844449 · 174 participants (planned) · Start Aug 11, 2023 · Primary completion Jul 30, 2029
Drug: VNZ/TEZ/D-IVA · For: Cystic Fibrosis
Sites: Orange, California; Palo Alto, California; Aurora, Colorado · 37 sites in all
- Study of VX-121 in Healthy Subjects and in Subjects With Cystic FibrosisPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT03768089 · 115 participants · Start Mar 20, 2018 · Primary completion May 3, 2019
Drug: Placebo (matched to VX-121 suspension); VX-121 (Suspension) and 6 more · For: Cystic Fibrosis
Sites: Amsterdam, Netherlands; Groningen, Netherlands; Nijmegen, Netherlands · 7 sites in all
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT03912233 · 87 participants · Start Apr 30, 2019 · Primary completion Dec 10, 2019
Drug: VX-121; TEZ and 4 more · For: Cystic Fibrosis
Sites: Los Angeles, California; Oakland, California; Lexington, Kentucky · 26 sites in all
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06299709 · 34 participants · Start Mar 13, 2024 · Primary completion May 23, 2024
Drug: VNZ/TEZ/D-IVA; VNZ/TEZ/D-IVA · For: Cystic Fibrosis
Sites: Tempe, Arizona
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07349394 · 18 participants · Start Jan 12, 2026 · Primary completion Feb 28, 2026
Drug: VNZ/TEZ/D-IVA; Rosuvastatin · For: Cystic Fibrosis
Sites: Overland Park, Kansas
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05535959 · 16 participants · Start Sep 15, 2022 · Primary completion Nov 9, 2022
Drug: VX-121/TEZ/D-IVA · For: Cystic Fibrosis
Sites: Salt Lake City, Utah
Newest research
PubMed records naming it or its code names, newest first.
- Evaluation of potential relationship between CFTR modulators, CFTR and neuropsychiatric symptoms in CF.
Van Goor F, Francioli L, Sosnay PR, et al. · J Cyst Fibros 2026
- In Vitro Responsiveness of 417 CFTR Variants to Vanzacaftor/Tezacaftor/Ivacaftor.
Bihler H, Sivachenko A, Bhatt P, et al. · J Cyst Fibros 2026
- Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment.
Capurro V, Pesce E, Cresta F, et al. · J Cyst Fibros 2026
- Decreased pulmonary exacerbations and lower intravenous antibiotic usage following vanzacaftor/tezacaftor/deutivacaftor treatment in people with cystic fibrosis with F508del-minimal function genotypes.
Horsley A, Arteaga-Solis E, Keating C, et al. · Eur Respir J 2026
- Profiling the CFTR Variant Selectivity and Off-Target Interactions of VX-121.
Jhangiani AR, Olson JA, Tedman A, et al. · bioRxiv 2026
Also in development for Cystic Fibrosis
- ARCT-032Phase 21 trial
Arcturus Therapeutics, Inc. · Cystic Fibrosis, CFTR Gene Mutation
- CMTX-101Phase 21 trial
Clarametyx Biosciences, Inc. · Persistent Infection, Cystic Fibrosis
- ETD001Phase 21 trial
Enterprise Therapeutics Ltd · Cystic Fibrosis
- RCT2100Phase 21 trial
ReCode Therapeutics · Cystic Fibrosis
- SPL84Phase 21 trial
SpliSense Ltd. · Cystic Fibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Vertex Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.